Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22969010 | 0.77 | RIPK1 (0.40) | DDB1CRBNRIPK1SCN9AHTR2C | |
| SCHEMBL19960758 | 0.77 | NR1I2 (0.42) | DDB1CRBNRIPK1HTR2CSLC6A4 | |
| SCHEMBL22737131 | 0.77 | RIPK1 (0.52) | CRBNRIPK1SCN9A | |
| SCHEMBL28714243 | 0.77 | RIPK1 (0.52) | CRBNRIPK1SCN9A | |
| SCHEMBL19961242 | 0.76 | PSEN1 (0.39) | SCN9AHTR2CSLC6A4HTR2A | |
| SCHEMBL19961238 | 0.75 | NR1I2 (0.36) | DDB1CRBNRIPK1HTR2CSLC6A4 | |
| SCHEMBL22525924 | 0.75 | PYGL (0.41) | DDB1CRBNRIPK1 | |
| SCHEMBL23554702 | 0.72 | DDB1 (0.37) | DDB1CRBN | |
| SCHEMBL30304239 | 0.72 | DDB1 (0.37) | DDB1CRBN | |
| SCHEMBL25551342 | 0.70 | RIPK1 (0.43) | DDB1CRBNRIPK1HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | BISICHEM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040115-A1 | FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS | RIPK1, RIPK3, RIPK4 | DDB1 1028/4885CRBN 4478/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.